Sio Gene Therapies

Recent executive movements at Sio Gene Therapies

Kristin Vuori has joined the company as Director  (news posted on October 20 2020).
Kristiina Vuori has joined the company as Director  (news posted on October 9 2020).
Parag Meswani, who was Senior Vice President, Commercial Strategy and Operations, is promoted to Chief Commercial Officer  (news posted on October 9 2020).

Create an alert
to follow the executive moves at Sio Gene Therapies.

Most searched biographies at Sio Gene Therapies

• Pavan Cheruvu, Chief Executive Officer and Director
• Frank Torti, Chairman of the Board
• Senthil Sundaram, Director

Click on an executive to view his biography >

Latest M&A news in Biotechnology.

Kymab and Sanofi have announced they will merge (posted on Jan 11, 2021).
PerkinElmer has announced the acquisition of Oxford Immunotec (posted on Jan 8, 2021).
Syneos Health has announced the acquisition of SynteractHCR (posted on Dec 18, 2020).

Other contacts in the Biotechnology industry

• Chandra Leo - Director at Gynesonics
• Tal Zaks - Non-Executive Director at Adaptimmune Therapeutics
• Jean-Marc Roelandt - Chief Financial Officer at Biocartis

Learn more about the Biotechnology industry >

Latest news about Sio Gene Therapies

Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease - Axovant Gene Therapies
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis - Axovant Gene Therapies
Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer - Axovant Gene Therapies
Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy - Axovant Gene Therapies
Press Releases - Axovant Gene Therapies

Sio Gene Therapies on Wikipedia, Google News & Yahoo Finance

Sio Gene Therapies on LinkedIn, Twitter & YouTube

Sio Gene Therapies has 1,540 competitors including Biogen (United States (USA)), Agilyx (United States (USA)) and Eurofins (France). Sio Gene Therapies is owned by Roivant Sciences.

Contact by email its executives including Pavan Cheruvu

Call Sio Gene Therapies at +1441 441....

View the org chart

Register to receive your alert

Report an error